# Patent Watch: Lonza Pairs Cannabinoids With Muscul

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/patent-watch-patent-watch-lonza-pairs-cannabinoids-with-mu-2026-10-05/
> **Published:** 2026-10-05T12:26:16-04:00 | **Last Modified / Clinically Audited:** 2026-10-06T11:51:50-04:00
> **Clinical Summary:** The application appears to claim a cannabinoid-containing product combined with collagen or related protein and lipid components for musculoskeletal health

---

PATENT WATCH
 US20260263565A1
 
 

# Patent Watch: Lonza Pairs Cannabinoids With Musculoskeletal Nutrition

 
 **Assignee:** Lonza Greenwood LLC
 **Inventors:** Kevin Owen
 **Published:** 2026-09-10
 
 

 
 Invention Summary & Claims
 

The application appears to claim a cannabinoid-containing product combined with collagen or related protein and lipid components for musculoskeletal health, potentially across human nutrition and animal feed applications. Cannabinoids are the principal pharmacologically active ingredients, while collagen, proteins, fats, and formulation materials may function as nutritional co-components, carriers, or excipients depending on the specific claims.

 

 

## Clinical Perspective & Therapeutic Significance

 

An oral nutritional formulation could offer convenient administration, but bioavailability will depend on the cannabinoid, dose, lipid matrix, and manufacturing method. Patients should not assume benefits for pain, cartilage repair, muscle recovery, or joint function without controlled clinical evidence, and cannabinoid-related sedation, drug interactions, and product variability remain relevant safety considerations.

 

## Intellectual Property & Market Landscape

 

Lonza Greenwood LLC is affiliated with Lonza, a major contract development and manufacturing organization with expertise in dosage forms, encapsulation, and ingredient delivery. This IP may position Lonza to supply differentiated cannabinoid products beyond standard oils and gummies by linking cannabinoids with collagen-based musculoskeletal nutrition, although the patent alone does not demonstrate commercial readiness or therapeutic superiority.

 
 **Official Source Document:** Review the primary patent disclosure and full claims on [Google Patents (US20260263565A1)](https://patents.google.com/patent/US20260263565A1/en).
 

 
 Editorial Commentary
 

This filing reflects growing interest in combining cannabinoids with established joint and connective-tissue supplement categories. Its practical value will depend on transparent dosing, pharmacokinetic data, and clinical studies showing benefits beyond those of either component alone.

 

 
 

### Frequently Asked Questions

 
 Could this cannabinoid product rebuild cartilage or treat joint disease?
 The patent summary does not establish cartilage regeneration or treatment of arthritis. Any such benefit would require appropriately designed clinical trials using the claimed formulation and doses.

 Does publication of this patent mean the product has succeeded in clinical trials?
 No. Patent publication concerns intellectual property claims and does not confirm clinical efficacy, regulatory approval, or comparative safety.

 When could this product become available to patients?
 No reliable timeline can be determined from the patent alone. Availability will depend on product development, cannabinoid regulations, manufacturing decisions, and whether the intended claims require regulatory review.

 

 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 
 Physician-Led, Whole-Person Care
 A doctor who takes the time to truly understand you.
 Personal care that starts with listening and is guided by experience and ingenuity.
 
 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Cannabis Consultation](https://cedclinic.com/book/)
 
 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).